Understand ... IMO bisantrene has been proven ... just so few know. This is also supported by the exec funding arrangements and the recent arrival of DrT. (The pity is bisantrene hasn't been made available to those that need it until recently.)
It's the corporate activity and financing that both is the news and validation for continued investor support.
If anyone knows what bisantrene's potential is it's the BOD, look at their expertise and professional histories ... the trial in Israel should validate what they already appear to think through their funding and recent appointment. Of that I have no doubt.
RAC Charts, page-172
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.89 |
Change
0.120(6.80%) |
Mkt cap ! $321.0M | |||
| Open | High | Low | Value | Volume |
| $1.78 | $1.93 | $1.78 | $563.4K | 302.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 108 | $1.88 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.90 | 4926 | 1 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |